Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • CA-074: Selective Cathepsin B Inhibitor for Cancer Metast...

    2026-01-23

    CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis Research

    Principle Overview: Targeting Cathepsin B in Pathological Proteolysis

    Cathepsin B, a cysteine protease, plays a pivotal role in proteolytic cascades driving cancer metastasis, neurotoxicity, and immune dysregulation. Aberrant cathepsin B activity is implicated in the degradation of extracellular matrices, promoting tumor invasion and facilitating the spread of cancer cells. Its involvement extends to lysosome-mediated cell death and immune response modulation, making it a high-value target for both mechanistic and translational studies.

    CA-074, Cathepsin B inhibitor (SKU: A1926), supplied by APExBIO, is a potent and selective small molecule designed precisely to inhibit cathepsin B with nanomolar affinity (Ki = 2-5 nM), while demonstrating remarkable selectivity over related cathepsins H and L (Ki = 40–200 µM). This unique selectivity profile enables researchers to interrogate cathepsin B-mediated pathways in cancer metastasis, necroptosis, and immune regulation without confounding off-target effects.

    Experimental Workflow: Integrating CA-074 in Bench Research

    1. Preparation and Storage

    • Dissolve CA-074 in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), or water (>5.91 mg/mL using ultrasonic assistance) to constitute a working stock. For aqueous solutions, ensure ultrasonic agitation for optimal solubility.
    • Store aliquots at -20°C. For best results, use solutions freshly or within a short-term window to avoid degradation.

    2. In Vitro Application: Cell Culture Protocol

    • Add CA-074 to culture media at a final concentration determined by experimental design (commonly 1–10 μM for mechanistic studies).
    • For necroptosis or cancer invasion assays, pre-treat cells with CA-074 30–60 minutes before stimulation with relevant inducers (e.g., TNF, Smac-mimetic, Z-VAD-FMK for necroptosis).
    • Monitor cell viability, lysosomal integrity, or invasion/migration endpoints as appropriate.
    • CA-074 shows negligible cytotoxicity at concentrations up to 10 mM (cell viability >95% in most standard cell lines).

    3. In Vivo Application: Murine Model Guidance

    • Administer CA-074 via intraperitoneal injection at 50 mg/kg in mouse models of cancer metastasis (e.g., 4T1.2 breast cancer bone metastasis model).
    • Repeat dosing schedule as per study protocol (e.g., daily or every other day for 1–2 weeks).
    • Monitor metastasis endpoints (e.g., bone lesions by imaging or histology); note that CA-074 selectively reduces metastatic burden without affecting primary tumor growth.

    4. Enhanced Experimental Setups

    • Combine CA-074 with live-cell imaging (e.g., LysoTracker Red, Sytox Green, or Green Dextran beads) to visualize lysosomal membrane permeabilization (LMP) and cathepsin B release during necroptosis, as detailed in the MLKL polymerization-induced lysosomal membrane permeabilization study.
    • Implement in cytokine profiling and IgE/IgG1 quantification assays to explore immune response modulation, specifically Th-2 to Th-1 helper T cell switching.

    Advanced Applications and Comparative Advantages

    1. Dissecting Cathepsin B-Mediated Proteolytic Pathways in Metastasis

    Using CA-074, researchers can selectively inhibit cathepsin B in tumor cell lines and in vivo models to evaluate the enzyme's role in extracellular matrix remodeling, invasion, and the metastatic process. Notably, CA-074's nanomolar potency ensures effective blockade of cathepsin B activity while sparing closely related proteases, thus avoiding unintended effects on cathepsin H or L.

    In the 4T1.2 mouse model of breast cancer, treatment with CA-074 (50 mg/kg, i.p.) resulted in a significant reduction in bone metastases, as measured by histological bone lesion analysis, without impacting the growth of primary tumors. This highlights CA-074’s utility in dissecting site- and pathway-specific contributions of cathepsin B to cancer progression.

    2. Probing Necroptosis and Lysosomal Cell Death

    Recent mechanistic insights have spotlighted the role of cathepsin B in necroptosis, a regulated form of immunogenic cell death. In a landmark study (Cell Death & Differentiation, 2024), MLKL polymerization was shown to induce lysosomal membrane permeabilization (LMP), releasing active cathepsin B into the cytosol and precipitating cell death. Chemical inhibition of cathepsin B with CA-074 robustly protected cells from necroptosis, confirming its central role in this pathway.

    These findings enable researchers to leverage CA-074 for probing the temporal and mechanistic aspects of LMP, cathepsin B release, and downstream cell death signaling in cancer, neurodegeneration, and inflammation models.

    3. Immune Response Modulation

    CA-074 has demonstrated capacity to shift helper T cell responses from Th-2 to Th-1, resulting in decreased IgE/IgG1 production. This makes it a valuable tool for immunologists investigating the balance between humoral and cellular immunity in pathological and therapeutic contexts.

    4. Neurotoxicity and Neuroprotection

    In neuronal models, CA-074 effectively suppresses neurotoxic effects induced by Abeta42-activated microglial cells, supporting its use in studies of neurodegeneration and lysosome-related neuronal cell death.

    Comparative Literature Integration

    Troubleshooting and Optimization Tips

    • Solubility Challenges: For aqueous applications, always use ultrasonic agitation to achieve full dissolution. DMSO and ethanol stocks are typically more straightforward, but confirm complete solubility by visual inspection.
    • Stability: Store CA-074 at -20°C, protected from light and moisture. Prepare working solutions immediately prior to use, as the compound may degrade with prolonged storage in solution.
    • Cell Viability Controls: Although CA-074 is non-cytotoxic up to 10 mM, always include vehicle and untreated controls to confirm lack of off-target toxicity in novel cell systems.
    • Correct Dosing in Animal Models: For in vivo studies, adhere to the validated 50 mg/kg i.p. dosing regimen. Pilot studies can help optimize frequency and duration for specific disease models.
    • Pathway Specificity: To ensure that observed effects are due to cathepsin B inhibition, consider parallel experiments with genetic knockdown or alternative inhibitors as negative/positive controls.
    • Readout Selection: When dissecting necroptosis, combine CA-074 with live-cell imaging (e.g., LysoTracker Red, Sytox Green) and biochemical assays (e.g., cathepsin B activity, caspase activation, plasma membrane permeability) for robust mechanistic conclusions.
    • Batch Consistency: Source CA-074 from a trusted supplier such as APExBIO to ensure reproducibility and batch-to-batch consistency.

    Future Outlook: Expanding the Impact of Cathepsin B Inhibition

    CA-074's exceptional selectivity and nanomolar potency position it as an indispensable tool in the molecular dissection of proteolytic and immune mechanisms in disease. Upcoming research directions include:

    • Development of next-generation selective cathepsin B inhibitors with enhanced bioavailability and pharmacokinetics for clinical translation.
    • Integration of CA-074 in multi-omics workflows to unravel cathepsin B's broader network in tumor microenvironments, neurodegeneration, and immune modulation.
    • Utilization in precision immunotherapy strategies, leveraging its ability to modulate Th-2 to Th-1 helper T cell activity and influence the immune milieu in cancer and autoimmunity.

    For cutting-edge laboratories focused on cancer metastasis, necroptosis, and immune response modulation, CA-074—especially when sourced from APExBIO—remains the gold standard for selective, reliable, and reproducible inhibition of cathepsin B in both basic and translational research.